cinacalcet has been researched along with Kidney Diseases in 57 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 31 (54.39) | 29.6817 |
| 2010's | 25 (43.86) | 24.3611 |
| 2020's | 1 (1.75) | 2.80 |
| Authors | Studies |
|---|---|
| Christopoulos, A; Conigrave, AD; Davey, AE; Leach, K; Sexton, PM; Valant, C | 1 |
| Bracke, K; Braun, F; Choi, HY; Endlich, N; Guse, AH; Heidelbach, HS; Hermans-Borgmeyer, I; Hoffmann, GF; Huber, TB; Lassé, M; Lim, BJ; Meyer-Schwesinger, C; Mühlig, AK; Oh, J; Patry, C; Puelles, VG; Rinschen, MM; Sachs, W; Schmitt, CP; Steingröver, J; Weiß, M; Wingerath, M | 1 |
| Abdalla, S; Chertow, GM; Decker, BS; Foroud, TM; Lai, D; Long, J; Moe, SM; Vatta, M; Wetherill, L | 1 |
| Eller, K; Fahrleitner-Pammer, A; Kienreich, K; Pieske, B; Pilz, S; Ritz, E; Tomaschitz, A; Verheyen, N | 1 |
| Chu, M; Holt, SG; Hughes, PD; Jayadeva, P; Masterson, R; Sharma, AK; Tan, SJ; Toussaint, ND | 1 |
| Floege, J; Schlieper, G | 1 |
| Fernández Giráldez, ED | 1 |
| Borchhardt, KA; Haas, M; Heinzl, H; Hörl, WH; Mayerwöger, E; Sunder-Plassmann, G | 1 |
| Charytan, C; Corry, DB; Fishbane, S; Goodman, WG; Ling, X; Rappaport, K; Roppolo, M; Shapiro, WB; Turner, S; Vicks, SL | 1 |
| Fukagawa, M; Komaba, H | 1 |
| Belozeroff, V; Goodman, WG; Kalantar-Zadeh, K; Ren, L | 1 |
| Hamano, T | 2 |
| Tominaga, Y | 2 |
| Yokoyama, K | 2 |
| Curzi, MP; Evenepoel, P; González, MT; Husserl, FE; Kopyt, N; Mix, C; Sprague, SM; Sterling, LR; Wong, G | 1 |
| Shaheen, FA; Souqiyyeh, MZ | 1 |
| Błazejewska, A; Flisiński, M; Manitius, J; Pypkowski, J | 1 |
| Grzegorzewska, AE | 1 |
| Brown, EM | 1 |
| Taniguchi, M | 1 |
| Koiwa, F; Maruta, Y | 1 |
| Kakuta, T; Uemura, K | 1 |
| Fujii, N; Hamano, T; Imai, E; Isaka, Y; Matsui, I; Mikami, S; Rakugi, H; Tomida, K | 1 |
| Okimoto, N; Oshiro, Y; Tanaka, H | 1 |
| Goto, N; Hiramitsu, T; Izumi, K; Nanmoku, K; Nobata, H; Okada, M; Tominaga, Y; Tsujita, M; Uchida, K; Watarai, T; Yamamoto, T | 1 |
| Fukagawa, M; Kakuta, T; Koizumi, M; Komaba, H; Tanaka, H | 1 |
| Iino, Y; Wada, K; Wada, Y | 1 |
| Amdahl, M; Audhya, P; Cozzolino, M; Dumas, E; Goldsmith, D; Ketteler, M; Khan, S; Martin, KJ; Marx, S; Sharma, A | 1 |
| Cornago, I; Gallardo, I; García-Ledesma, P; Hernando, A; Martinez, I; Montenegro, J; Muñoz, RI; Romero, MA | 1 |
| Akizawa, T; Mizobuchi, M; Nakazawa, A | 1 |
| Fukagawa, M; Kakuta, T; Koizumi, M; Komaba, H; Sawada, K; Takahashi, H; Tanaka, H | 1 |
| Fliser, D; Heine, GH; Ketteler, M; Seiler, S | 1 |
| Hosoya, T; Ishida, M; Iwamoto, T; Ohkido, I; Urashima, M; Yokoyama, K | 1 |
| Imanishi, Y | 1 |
| Cases, A | 2 |
| Cattley, RC; Colloton, M; Henley, C; Lacey, D; Martin, D; Shatzen, E; Towler, DA | 1 |
| Harris, RZ; Padhi, D; Salfi, M; Sullivan, JT | 1 |
| Goodman, WG | 1 |
| Quarles, LD | 1 |
| Charytan, C; Chonchol, M; Coburn, JW; Herman, J; Klassen, PS; Lien, YH; Liu, W; McCary, LC; Pichette, V | 1 |
| Fournier, A; Harbouche, L; Monge, M; Shahapuni, I | 1 |
| Craig, JC; Elder, G; Messa, P; Palmer, S; Strippoli, GF; Tong, A | 1 |
| Drüeke, TB; Landais, P | 1 |
| Arias, M; de Francisco, AL; Palomar, R; Piñera, C | 1 |
| Fadem, SZ; Moe, SM | 1 |
| Alvarez-Ude, F; Arenas, MD; Carretón, MA; Devesa, R; Gil, MT; Malek, T; Moledous, A; Nuñez, C; Soriano, A | 1 |
| Brancaccio, D; Cozzolino, M; Galassi, A | 1 |
| Block, G | 1 |
| Bommer, J; Brancaccio, D; Coyne, D | 1 |
| Amado, JA; Arias, M; Cunningham, J; de Francisco, AL; Fresnedo, GF; Izquierdo, M; Palomar, R; Piñera, C; Unzueta, MG | 1 |
| Brancaccio, D; Cozzolino, M; Fallabrino, G; Galassi, A; Gallieni, M; Pasho, S | 1 |
25 review(s) available for cinacalcet and Kidney Diseases
| Article | Year |
|---|---|
Cinacalcet hydrochloride for the treatment of hyperparathyroidism.
Topics: Calcimimetic Agents; Cinacalcet; Cost-Benefit Analysis; Humans; Hyperparathyroidism; Kidney Diseases; Naphthalenes; Parathyroid Hormone; Severity of Illness Index | 2013 |
Calcimimetics in CKD-results from recent clinical studies.
Topics: Chronic Disease; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Kidney Transplantation; Naphthalenes; Renal Dialysis | 2008 |
[Clinical advances in vascular calcification].
Topics: Aged; Animals; Atherosclerosis; Calcinosis; Chronic Disease; Cinacalcet; Coronary Artery Disease; Diabetes Complications; Ergocalciferols; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Kidney Diseases; Mice; Mice, Knockout; Multicenter Studies as Topic; Naphthalenes; Polyamines; Randomized Controlled Trials as Topic; Renal Artery; Sevelamer; Tomography, Spiral Computed; Tomography, X-Ray Computed; Vascular Diseases | 2008 |
[Chronic kidney disease (CKD) and bone. Control of CKD-MBD from the viewpoint of the medical cost].
Topics: Bone Diseases, Metabolic; Chelating Agents; Chronic Disease; Cinacalcet; Cost-Benefit Analysis; Costs and Cost Analysis; Economics, Pharmaceutical; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Naphthalenes; Parathyroidectomy; Policy Making; Polyamines; Sevelamer; Vitamin D | 2009 |
[Chronic kidney disease (CKD) and bone. The clinical perspective of parathyroid interventional therapy for advanced secondary hyperparathyroidism in the era of cinacalcet HCl].
Topics: Chronic Disease; Cinacalcet; Drug Therapy, Combination; Ethanol; Humans; Hyperparathyroidism, Secondary; Injections, Intralesional; Kidney Diseases; Naphthalenes; Parathyroidectomy; Renal Dialysis; Vitamin D | 2009 |
[Chronic kidney disease (CKD) and bone. Vascular calcification in CKD].
Topics: Animals; Calcinosis; Calcium; Chelating Agents; Chronic Disease; Cinacalcet; Diphosphonates; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperphosphatemia; Kidney Diseases; Naphthalenes; Phosphates; Polyamines; Prognosis; Randomized Controlled Trials as Topic; Rats; Sevelamer; Vascular Diseases | 2009 |
[Calcimimetic drugs in nondialyzed patients].
Topics: Chronic Disease; Cinacalcet; Disease Progression; Humans; Hyperparathyroidism; Kidney Diseases; Kidney Transplantation; Naphthalenes; Parathyroid Hormone | 2010 |
Clinical utility of calcimimetics targeting the extracellular calcium-sensing receptor (CaSR).
Topics: Animals; Biomimetic Materials; Calcium; Cinacalcet; Drug Delivery Systems; Extracellular Fluid; Humans; Kidney Diseases; Naphthalenes; Protein Structure, Secondary; Receptors, Calcium-Sensing | 2010 |
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Paradigm shift in CKD-MBD guideline].
Topics: Bone Density; Bone Diseases, Metabolic; Chronic Disease; Cinacalcet; Dialysis; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Lanthanum; Naphthalenes; Practice Guidelines as Topic | 2010 |
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). The impact of CKD-MBD on mortality].
Topics: Bone Diseases, Metabolic; Calcinosis; Calcium; Chronic Disease; Cinacalcet; Humans; Kidney Diseases; Naphthalenes; Parathyroid Hormone; Phosphorus; Polyamines; Prognosis; Risk; Sevelamer; Survival Rate; Vascular Diseases; Vitamin D | 2010 |
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Role of cinacalcet in the treatment of CKD-MBD].
Topics: Bone Diseases, Metabolic; Calcinosis; Calcium; Chronic Disease; Cinacalcet; Clinical Trials as Topic; Drug Therapy, Combination; Fractures, Bone; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Naphthalenes; Parathyroid Hormone; Phosphorus; Vascular Diseases; Vitamin D | 2010 |
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Parathyroid interventions: final one piece in the management of uremic SHPT patients].
Topics: Bone Diseases, Metabolic; Calcitriol; Chelating Agents; Chronic Disease; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Naphthalenes; Parathyroidectomy; Polyamines; Practice Guidelines as Topic; Receptors, Calcium-Sensing; Sevelamer; Uremia; Vitamin D | 2010 |
[Bone and calcium update; diagnosis and therapy of metabolic bone disease update. Advances in treatment of CKD-MBD].
Topics: Bone Diseases, Metabolic; Chronic Disease; Cinacalcet; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Klotho Proteins; Lanthanum; Membrane Proteins; Naphthalenes; Vascular Calcification; Vitamin D | 2011 |
[Kidney and bone update : the 5-year history and future of CKD-MBD. Bone fragility in the aged hemodialysis patients].
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Chronic Disease; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Diphosphonates; Fractures, Spontaneous; Homeostasis; Humans; Kidney Diseases; Minerals; Naphthalenes; Osteoporosis; Phosphorus; Renal Dialysis; Risk | 2012 |
[Kidney and bone update : the 5-year history and future of CKD-MBD. Pharmacoeconomics in the field of CKD-MBD].
Topics: Bone Diseases, Metabolic; Carbamates; Chelating Agents; Chronic Disease; Cinacalcet; Cost-Benefit Analysis; Humans; Kidney Diseases; Lanthanum; Minerals; Naphthalenes; Parathyroidectomy; Polyamines; Sevelamer; Vitamin D | 2012 |
[Kidney and bone update : the 5-year history and future of CKD-MBD. Parathyroidectomy for secondary hyperparathyroidism].
Topics: Chronic Disease; Cinacalcet; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Hyperphosphatemia; Japan; Kidney Diseases; Naphthalenes; Parathyroidectomy; Practice Guidelines as Topic | 2012 |
Cinacalcet: AMG 073, Calcimimetics--Amgen/NPS Pharmaceuticals, KRN 1493, NPS 1493.
Topics: Chronic Disease; Cinacalcet; Clinical Trials as Topic; Humans; Hyperparathyroidism; Hyperparathyroidism, Secondary; Kidney Diseases; Naphthalenes | 2003 |
Update in nephrology. Highlights from the 36th Annual Meeting of the American Society of Nephrology.
Topics: Anemia; Chronic Disease; Cinacalcet; Clinical Trials as Topic; Congresses as Topic; Diabetic Nephropathies; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Naphthalenes; Nephrology | 2004 |
Calcimimetics: a remedy for all problems of excess parathyroid hormone activity in chronic kidney disease?
Topics: Animals; Chronic Disease; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Naphthalenes; Parathyroid Glands; Parathyroid Hormone | 2005 |
Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease.
Topics: Chronic Disease; Cinacalcet; Clinical Trials as Topic; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Naphthalenes; Practice Guidelines as Topic; Receptors, Calcium-Sensing | 2005 |
Meta-analysis of biochemical and patient-level effects of calcimimetic therapy.
Topics: Aniline Compounds; Calcium; Chronic Disease; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Naphthalenes; Phenethylamines; Propylamines; Randomized Controlled Trials as Topic | 2006 |
Impact of treatment with calcimimetics on hyperparathyroidism and vascular mineralization.
Topics: Calcinosis; Calcium; Chronic Disease; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Naphthalenes; Vascular Diseases | 2006 |
Management of chronic kidney disease mineral-bone disorder.
Topics: Bone Density Conservation Agents; Bone Diseases; Calcifediol; Chronic Disease; Cinacalcet; Diet; Humans; Hyperparathyroidism; Kidney Diseases; Kidney Failure, Chronic; Minerals; Naphthalenes; Parathyroid Hormone; Phosphates; Phosphorus; Vitamin D | 2007 |
Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies.
Topics: Animals; Bone Density Conservation Agents; Calcitriol; Chronic Disease; Cinacalcet; Ergocalciferols; Humans; Hydroxycholecalciferols; Hyperparathyroidism, Secondary; Kidney Diseases; Naphthalenes; Receptors, Calcitriol; Vitamin D | 2007 |
Preventive measures and new pharmacological approaches of calcium and phosphate disorders.
Topics: Calcium; Chronic Disease; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Lanthanum; Naphthalenes; Phosphates; Polyamines; Renal Dialysis; Sevelamer; Vitamin D | 2008 |
9 trial(s) available for cinacalcet and Kidney Diseases
| Article | Year |
|---|---|
Calcium-Sensing Receptor Genotype and Response to Cinacalcet in Patients Undergoing Hemodialysis.
Topics: Adult; Aged; Alkaline Phosphatase; Biomarkers; Black People; Calcimimetic Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Female; Fibroblast Growth Factor-23; Gene Frequency; Humans; Kidney Diseases; Linkage Disequilibrium; Male; Middle Aged; Parathyroid Hormone; Pharmacogenetics; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Receptors, Calcitriol; Receptors, Calcium-Sensing; Renal Dialysis; Time Factors; Treatment Outcome; White People | 2017 |
Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results.
Topics: Adult; Aged; Calcium; Chronic Disease; Cinacalcet; Drug Therapy, Combination; Female; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Practice Guidelines as Topic; Prospective Studies; Renal Dialysis; Time Factors; Treatment Outcome; Vitamin D; Vitamins | 2008 |
Cinacalcet lowers serum alkaline phosphatase in maintenance hemodialysis patients.
Topics: Adult; Aged; Alkaline Phosphatase; Australia; Calcium; Cinacalcet; Double-Blind Method; Down-Regulation; Europe; Female; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Renal Dialysis; Time Factors; Treatment Outcome; United States | 2009 |
Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl.
Topics: Adult; Aged; Biomarkers; Calcium; Canada; Chelating Agents; Chronic Disease; Cinacalcet; Double-Blind Method; Drug Therapy, Combination; Europe; Female; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Peritoneal Dialysis; Phosphates; Phosphorus; Renal Dialysis; Time Factors; Treatment Outcome; United States; Vitamin D | 2009 |
Novel electrochemiluminescence immunoassay exclusively for full-length parathyroid hormone during treatment with cinacalcet for secondary hyperparathyroidism.
Topics: Aged; Cinacalcet; Electrochemistry; Female; Humans; Hyperparathyroidism, Secondary; Immunoassay; Immunoradiometric Assay; Kidney Diseases; Luminescent Measurements; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Renal Dialysis | 2011 |
Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Calcimimetic Agents; Cinacalcet; Cohort Studies; Disease Management; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergocalciferols; Female; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Male; Middle Aged; Naphthalenes; Practice Guidelines as Topic; Renal Dialysis; Treatment Outcome; Vitamin D | 2012 |
Efficacy and safety of cinacalcet for the treatment of secondary hyperparathyroidism in patients with advanced chronic kidney disease before initiation of regular dialysis.
Topics: Adult; Aged; Calcimimetic Agents; Calcium; Chronic Disease; Cinacalcet; Compassionate Use Trials; Drug Therapy, Combination; Female; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Severity of Illness Index; Treatment Outcome; Vitamin D | 2012 |
Effects of cinacalcet treatment on serum soluble Klotho levels in haemodialysis patients with secondary hyperparathyroidism.
Topics: Aged; Calcimimetic Agents; Calcium; Cinacalcet; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glucuronidase; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Klotho Proteins; Longitudinal Studies; Male; Middle Aged; Naphthalenes; Phosphorus; Renal Dialysis; Treatment Outcome | 2012 |
Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis.
Topics: Calcium; Chronic Disease; Cinacalcet; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Treatment Outcome; Vitamin D | 2005 |
23 other study(ies) available for cinacalcet and Kidney Diseases
| Article | Year |
|---|---|
Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor.
Topics: Allosteric Site; Aniline Compounds; Calcimimetic Agents; Calcium; Cell Membrane; Cinacalcet; HEK293 Cells; Humans; Hyperparathyroidism; Kidney Diseases; Kidney Failure, Chronic; Ligands; Naphthalenes; Phenethylamines; Phosphorylation; Propylamines; Receptors, Calcium-Sensing; Signal Transduction; Treatment Outcome | 2012 |
The calcium-sensing receptor stabilizes podocyte function in proteinuric humans and mice.
Topics: Animals; Calcium; Cinacalcet; Doxorubicin; Humans; Kidney Diseases; Mice; Mice, Knockout; Podocytes; Proteinuria; Receptors, Calcium-Sensing | 2022 |
Impact of cinacalcet pre-transplantation on mineral metabolism in renal transplant recipients.
Topics: Adult; Biomarkers; Calcimimetic Agents; Calcium; Cinacalcet; Drug Administration Schedule; Female; Graft Survival; Humans; Kidney Diseases; Kidney Transplantation; Male; Middle Aged; Parathyroid Hormone; Parathyroidectomy; Renal Dialysis; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Victoria | 2016 |
Cinacalcet increases calcium excretion in hypercalcemic hyperparathyroidism after kidney transplantation.
Topics: Adult; Aged; Calcium; Cinacalcet; Female; Glomerular Filtration Rate; Humans; Hypercalcemia; Hyperparathyroidism; Immunosuppressive Agents; Kidney Diseases; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Naphthalenes; Postoperative Complications | 2008 |
Regression of parathyroid hyperplasia by calcimimetics--fact or illusion?
Topics: Calcitriol; Chronic Disease; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Hyperplasia; Kidney Diseases; Naphthalenes | 2009 |
Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Topics: Attitude of Health Personnel; Biomarkers; Bone Diseases, Metabolic; Calcium; Chelating Agents; Chronic Disease; Cinacalcet; Evidence-Based Medicine; Glomerular Filtration Rate; Guideline Adherence; Health Care Surveys; Health Knowledge, Attitudes, Practice; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Diseases; Naphthalenes; Parathyroid Hormone; Phosphorus; Practice Guidelines as Topic; Practice Patterns, Physicians'; Renal Dialysis; Saudi Arabia; Surveys and Questionnaires; Treatment Outcome; Vitamin D; Vitamin D Deficiency | 2010 |
[Patient with chronic kidney disease and primary or tertiary hyperparathyroidism--case report].
Topics: Adult; Chronic Disease; Cinacalcet; Female; Humans; Hypercalcemia; Hyperparathyroidism; Hypophosphatemia; Kidney Diseases; Naphthalenes | 2009 |
Fetuin-mineral complex reflects extraosseous calcification stress in CKD.
Topics: Aged; alpha-2-HS-Glycoprotein; Biomarkers; Blood Proteins; Calcinosis; Calcium; Case-Control Studies; Chronic Disease; Cinacalcet; Coronary Artery Disease; Female; Fibrinogen; Fibronectins; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Longitudinal Studies; Male; Middle Aged; Naphthalenes; Renal Dialysis; Severity of Illness Index | 2010 |
A patient undergoing chronic dialysis whose renal anemia was successfully corrected by treatment with cinacalcet.
Topics: Anemia; Calcimimetic Agents; Cinacalcet; Female; Humans; Hyperparathyroidism; Hyperparathyroidism, Secondary; Kidney Diseases; Kidney Failure, Chronic; Middle Aged; Naphthalenes; Parathyroid Hormone; Parathyroidectomy; Renal Dialysis | 2011 |
Tertiary hyperparathyroidism resistant to cinacalcet treatment.
Topics: Adult; Chronic Disease; Cinacalcet; Creatinine; Drug Resistance; Female; Humans; Hyperparathyroidism, Secondary; Hyperplasia; Kidney Diseases; Middle Aged; Naphthalenes; Parathyroid Glands; Parathyroidectomy; Treatment Outcome; Ultrasonography | 2011 |
Two cases of acute renal hemorrhage undergoing maintenance hemodialysis after concurrent administration of cinacalcet.
Topics: Adult; Calcimimetic Agents; Cinacalcet; Hematoma; Hemorrhage; Humans; Kidney Diseases; Male; Middle Aged; Naphthalenes; Radiography, Abdominal; Renal Dialysis; Tomography, X-Ray Computed | 2011 |
Measurement of serum soluble Klotho levels in CKD 5D patients: useful tool or dispensable biomarker?
Topics: Cinacalcet; Female; Glucuronidase; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Klotho Proteins; Male; Naphthalenes; Renal Dialysis | 2012 |
Decrease of serum sphingosine-1-phosphate levels in hemodialysis patients with secondary hyperparathyroidism treated with cinacalcet.
Topics: Aged; Biomarkers; Calcimimetic Agents; Chromatography, High Pressure Liquid; Cinacalcet; Down-Regulation; Female; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Lysophospholipids; Male; Middle Aged; Naphthalenes; Renal Dialysis; Sphingosine; Treatment Outcome | 2012 |
Molecule of the month. Cinacalcet hydrochloride.
Topics: Cinacalcet; Clinical Trials as Topic; Humans; Hyperparathyroidism; Kidney Diseases; Naphthalenes | 2003 |
1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism.
Topics: Animals; Aortic Diseases; Calcinosis; Calcitriol; Calcium; Calcium Channel Agonists; Chronic Disease; Cinacalcet; Disease Models, Animal; Hyperparathyroidism, Secondary; Kidney Diseases; Male; Naphthalenes; Parathyroid Hormone; Phosphorus; Rats; Rats, Sprague-Dawley | 2005 |
No effect of renal function or dialysis on pharmacokinetics of cinacalcet (Sensipar/Mimpara).
Topics: Adult; Aged; Calcium; Cinacalcet; Female; Humans; Kidney Diseases; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Renal Dialysis | 2005 |
The latest findings in basic and clinical nephrology science.
Topics: Anemia; Cinacalcet; Clinical Trials as Topic; Humans; Kidney Diseases; Kidney Transplantation; Lanthanum; Naphthalenes; Renal Dialysis | 2005 |
Calcimimetics for predialysis patients?
Topics: Calcifediol; Chronic Disease; Cinacalcet; Dose-Response Relationship, Drug; Humans; Hyperparathyroidism, Secondary; Hypocalcemia; Kidney Diseases; Naphthalenes; Parathyroid Hormone; Phosphates; Vitamin D; Vitamin D Deficiency | 2006 |
Paricalcitol for treatment of secondary hyperparathyroidism in CKD patients.
Topics: Acetates; Calcitriol; Calcium; Calcium Compounds; Chronic Disease; Cinacalcet; Clinical Trials, Phase III as Topic; Ergocalciferols; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Naphthalenes; Parathyroid Hormone; Phosphorus; Randomized Controlled Trials as Topic | 2006 |
Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
Topics: Bone and Bones; Bone Diseases, Metabolic; Chronic Disease; Cinacalcet; Female; Humans; Hyperparathyroidism; Kidney Diseases; Male; Middle Aged; Naphthalenes; Practice Guidelines as Topic; Renal Dialysis; Vitamin D | 2007 |
Cinacalcet, paricalcitol, or both?
Topics: Bone and Bones; Bone Diseases, Metabolic; Chronic Disease; Cinacalcet; Data Interpretation, Statistical; Drug Therapy, Combination; Humans; Hyperparathyroidism; Kidney Diseases; Naphthalenes; Practice Guidelines as Topic; Renal Dialysis; Vitamin D | 2007 |
Calcium, calcimimetics and clinical outcomes.
Topics: Calcium; Chronic Disease; Cinacalcet; Humans; Hyperparathyroidism; Kidney Diseases; Naphthalenes; Prognosis | 2006 |
Calcium-mediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcet.
Topics: Adult; Aged; Aged, 80 and over; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism; Kidney Diseases; Male; Middle Aged; Naphthalenes; Nephritis, Interstitial; Nephrosclerosis; Parathyroid Hormone; Polycystic Kidney Diseases; Receptors, Calcium-Sensing; Renal Dialysis | 2008 |